ABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Peritonitis/etiology , Mycoplasma hominis/pathogenicity , Peritoneal Dialysis/adverse effects , Renal Insufficiency, Chronic/therapy , Vesico-Ureteral Reflux/complicationsABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Peritoneal Dialysis/methods , Psychotropic Drugs/administration & dosage , Anxiety/drug therapy , Depression/drug therapy , Sleep Initiation and Maintenance Disorders/drug therapySubject(s)
Anxiety/drug therapy , Depression/drug therapy , Peritoneal Dialysis , Psychotropic Drugs/therapeutic use , Sleep Wake Disorders/drug therapy , Adult , Aged , Anxiety/etiology , Depression/etiology , Humans , Middle Aged , Peritoneal Dialysis/adverse effects , Sleep Wake Disorders/etiologySubject(s)
Pancreatitis/etiology , Polycystic Kidney Diseases/complications , Acute Disease , Humans , Male , Middle AgedABSTRACT
No disponible
No disponible
Subject(s)
Humans , Male , Middle Aged , Polycystic Kidney Diseases/complications , Pancreatitis, Acute Necrotizing/complications , Renal Dialysis , Fatty Liver/complicationsABSTRACT
No disponible
No disponible
Subject(s)
Humans , Peritoneal Dialysis/methods , Disinfection/methods , Asepsis/methods , Dialysis Solutions/analysisABSTRACT
No disponible
No disponible
Subject(s)
Humans , Male , Middle Aged , Granulomatosis with Polyangiitis/complications , Lung Neoplasms/complications , Renal Insufficiency, Chronic/therapy , Renal DialysisABSTRACT
The incidence of hemoperitoneum varies from 6% to 57% in premenopausal women. Bloody peritoneal dialysate may be the result of the peritoneal dialysis procedure or may be due to factors unrelated to renal disease. The Libman-Sacks endocarditis was described for the first time in 1924, is characterized for verrucous lesions in the surfaces valves and has been intimately associated with the presence of antiphospholipid antibodies. We send a case of a patient in program of Dialysis peritoneal that presented an Libman-Sacks endocarditis and hemoperitoneum.
Subject(s)
Endocarditis/complications , Hemoperitoneum/complications , Peritoneal Dialysis/adverse effects , Endocarditis/etiology , Female , Hemoperitoneum/etiology , Humans , Middle AgedABSTRACT
Chyloperitoneum is very infrequent in peritoneal dialysis. It has been described in patients diagnosed of systemic amyloidosis. We present the case of a patient in program of peritoneal dialysis, with familial amyloidosis type Andrade disease that presented intermittent and recidivante chyloperitoneum.
Subject(s)
Amyloidosis, Familial/complications , Chylous Ascites/etiology , Peritoneal Dialysis/adverse effects , Aged , Female , HumansABSTRACT
La incidencia de hemoperitoneo en diálisis varia del 6% hasta el 57% en mujeres premenopáusicas. El sangrado peritoneal puede ser el resultado de un proceso relacionado con la diálisis ono estar relacionado con la enfermedad renal. La endocarditis de Libman-Sacks se describió por primera vez en1924, se caracteriza por lesiones de tipo verrugoso implantadas en las superficies valvulares y está íntimamente ligada a la presencia de anticuerpos antifosfolípido. Enviamos el caso de una paciente en programa de Diálisis peritoneal que presentó una endocarditis de Libman-Sacks, y cursó con hemoperitoneo (AU)
The incidence of hemoperitoneum varies from 6% to 57% in premenopausal women. Bloody peritoneal dialysate maybe the result of the peritoneal dialysis procedure or may be due to factors unrelated to renal disease. The Libman-Sacks endocarditis was described for the first time in 1924, is characterized for verrucous lesions in the surfaces valves and has been intimately associated with the presence of antiphospholipid antibodies. We send a case of a patient in program of Dialysis peritoneal that presented an Libman-Sacks endocarditis and hemoperitoneum (AU)
Subject(s)
Humans , Female , Middle Aged , Hemoperitoneum/complications , Endocarditis/complications , Renal Insufficiency, Chronic/therapy , Peritoneal Dialysis , Antibodies, Antiphospholipid/isolation & purificationABSTRACT
El quiloperitoneo es una entidad rara en diálisis peritoneal. Se ha descrito en pacientes diagnosticados de amiloidosis sistémica. Presentamos el caso de una paciente en programa de diálisis peritoneal, con amiloidosis familiar tipo enfermedad de Andrade que cursó con quiloperitoneo intermitente y recidivante (AU)
Chyloperitoneum is very infrequent in peritoneal dialysis. It has been described in patients diagnosed of systemic amyloidosis. We present the case of a patient in program of peritoneal dialysis, with familial amyloidosis type Andrade disease that presented intermittent and recidivante chyloperitoneum (AU)
Subject(s)
Humans , Female , Aged , Chylous Ascites/complications , Amyloidosis/complications , Renal Insufficiency, Chronic/therapy , Peritoneal Dialysis , Diagnosis, DifferentialABSTRACT
Se describe el caso de una paciente con leucemia aguda promielocítica (LAP) que desarrolló síndrome del ácido transretinoico (SAR). ElSAR se presenta en enfermos con LAP tratados con ácido transretinoico (ATRA). Tiene incidencia de 5 a 27% con mortalidad de hasta 29%. Clínicamente se manifiesta con fiebre, hipotensión, insuficiencia respiratoria, renal y hepática, infiltrados pulmonares, derrame pleural y pericárdico, y edema generalizado. Es secundario al efecto del ATRA sobre la diferenciación de los promielocitos, lo que desencadena respuesta inflamatoria sistémica, daño endotelial con síndrome de fuga capilar y obstrucción de la microcirculación e infiltración tisular. El tratamiento consiste en la suspensión del ATRA, esteroides y medidas de soporte
We described a patient with acute promyelocytic leucemia (APL) who developed all-trans retinoic acid syndrome (ATRAS). ATRAS presents inpatients with APL treated with all-trans retinoic acid (ATRA). It has an incidence from 5-27% with mortality of 29%. ATRAS clinical manifestations are fever, hypotension, respiratory, renal and hepatic insufficiency, lung infiltrates, pleural and pericardic efussion, and generalized edema. It is secondary to ATRA effect on promyelocyte differentiation, which causes systemic inflammatory response syndrome, endothelium damage with increase in capillary permeability, microcirculation obstruction, and tissue infiltration. Treatment is based on ATRA suspension, steroids and support measures
Subject(s)
Humans , Female , Adult , Kidney Cortex Necrosis/chemically induced , Tretinoin/adverse effects , Kidney Cortex Necrosis/diagnosis , Tretinoin/metabolism , Leukemia, Promyelocytic, Acute/chemically induced , Leukemia, Promyelocytic, Acute/complicationsABSTRACT
We described a patient with acute promyelocytic leukemia (APL) who developed all-trans retinoic acid syndrome (ATRAS). ATRAS presents in patients with APL treated with all-trans retinoic acid (ATRA). It has an incidence from 5-27% with mortality of 29%. ATRAS clinical manifestations are fever, hypotension, respiratory, renal and hepatic insufficiency, lung infiltrates, pleural and pericardic effusion, and generalized edema. It is secondary to ATRA effect on promyelocyte differentiation, which causes systemic inflammatory response syndrome, endothelium damage with increase in capillary permeability, microcirculation obstruction, and tissue infiltration. Treatment is based on ATRA suspension, steroids and support measures.
Subject(s)
Antineoplastic Agents/adverse effects , Kidney Cortex Necrosis/chemically induced , Tretinoin/adverse effects , Adult , Female , Humans , Leukemia, Promyelocytic, Acute/drug therapy , SyndromeABSTRACT
No disponible
